AcquisitionsAug 7, 2026, 02:04 PM
Artivion Acquires Endospan for $178.1M; Q2 Net Loss $(13.5)M
AI Summary
Artivion, Inc. completed the acquisition of Endospan Ltd. on May 18, 2026, for a total consideration of $178.1 million, expanding its aortic arch product portfolio and recognizing $99.2 million in goodwill. Additionally, the company received FDA approval for the AMDS Hybrid Prosthesis in June 2026, triggering a $25.0 million contingent payment related to the Ascyrus acquisition. For the second quarter of 2026, Artivion reported increased total revenues of $125.8 million but swung to a net loss of $(13.5) million, or $(0.28) per basic share, compared to net income in the prior year.
Key Highlights
- Acquired Endospan on May 18, 2026, for a total consideration of $178.1 million.
- Recognized preliminary goodwill of $99.2 million from the Endospan acquisition.
- FDA approved the PMA application for the AMDS Hybrid Prosthesis in June 2026, triggering a $25.0 million contingent payment.
- Total revenues for Q2 2026 increased to $125.8 million from $113.0 million in Q2 2025.
- Reported a net loss of $(13.5) million for Q2 2026, compared to net income of $1.3 million in Q2 2025.
- Basic loss per share for Q2 2026 was $(0.28), down from $0.03 earnings per share in Q2 2025.
- Net cash flows used in operating activities for the six months ended June 30, 2026, were $(0.1) million.
- Net cash flows provided by financing activities for the six months ended June 30, 2026, were $152.9 million.
Price Impact
More from AORT